Lack of deals hits RaQualia as it looks to reverse widening losses
This article was originally published in Scrip
Executive Summary
RaQualia Pharma has unveiled a new mid-term business development plan that envisages a more than 10-fold jump in business revenues and a sharp reduction in its net loss over the next two years, driven by new licensing deals.